The role of forced degradation studies in stability indicating HPLC method development

American Pharmaceutical Review

Volumn 9, Issue 1, 2006, Pages 46-53

  Ruan, Joan ^a   Tattersall, Peter ^a   Lozano, Ruben ^a   Shah, Pankaj ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Drug substance; Forced degradation; HPLC; Stability indicating; Stress testing

Indexed keywords

ANALYTIC METHOD; ARTICLE; CHEMICAL REACTION; DEGRADATION KINETICS; EXERCISE TEST; GLACIAL MASS BALANCE; HEAT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMIDITY; HYDROLYSIS; LIGHT; OXIDATION; SPECTRAL SENSITIVITY;

EID: 55549113576     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Swartz M. and Krull I., (2005), "Developing and Validating Stability-Indicating Methods". LCGC North America, 23(6), 586-593.
2. Reynolds D.W., Facchine K.L, Mullaney J.F., Alsante K.M., Hatajik T.D., and Motto M.G., (2002), "Available Guidance & Best Practices for Conducting Forced Degradation Studies". Pharm Technol, 26(2), 48-56.
3. Reynolds D.W., (2004), "Forced Degradation of Pharmaceuticals". Am Pharm Rev, 7(3), 56-61.
4. Thatcher S.R, Mansfield R.K., Miller R.B, Davis C.W., and Baertschi S.W., (2001), "Pharmaceutical Photostability". Pharm Technol, 25(3), 98-110.
5. International Conference on Harmonization, "Stability Testing of New Drug Substances and Products," Q1A (R2), November 2003.
6. International Conference on Harmonization, "Stability Testing: Photostability Testing of New Drug Substance and Products," Q1B, November 1996.
7. International Conference on Harmonization, "Evaluation of Stability Data," Q1E, February 2003.
8. International Conference on Harmonization, "Impurities in New Drug Substances," Q3A(R), February 2003.
9. International Conference on Harmonization, "Impurities in New Drug Products," Q3B(R), November 2003.
10. International Conference on Harmonization, "Guidance on Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substance and Products: Chemical Substances," December 2000.
11. FDA Guidance for Industry: "INDs for Phase 2 and 3 Studies; Chemistry, Manufacturing, and Control Information," May 2003.
12. Alsante K.M., Martin L., and Baertschi S.W., (2003), "A Stress Testing Benchmarking Study". Pharm Technol, 27(2), 60-72.
13. Karcher B.D., Davies M.L., Venit J.J., and Delaney E.J., (2004), "Multi-Dimensional Screening and Analysis (MDSA): An Automated Tool for HPLC". Am Pharm Rev, 7(6), 62-66.
14. Hovorka S.W. and Schöneich C., (2001), "Oxidative Degradation of Pharmaceuticals: Theory, Mechanisms and Inhibition". J Pharm Sci, 90(3), 253-269.